Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms

An exploratory preclinical study compared metformin alone versus metformin plus ruxolitinib and found that metformin alone shows antileukemic activity and that the combination demonstrates increased cellular death in combination with ruxolitinib. This research provides insights for the development of synergistic combinations that may used in clinical trials. 

 Cell Death & Disease

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.